Home > Rheumatology > EULAR 2020 > Ankylosing Spondylitis > Reduced maintenance dose of certolizumab pegol can be used in axSpA

Reduced maintenance dose of certolizumab pegol can be used in axSpA

Presented By
Prof. Robert Landewé, University of Amsterdam, the Netherlands
Conference
EULAR 2020
Trial
C-OPTIMISE
Outcomes of the C-OPTIMISE trial show that a reduced maintenance dose of certolizumab pegol may be used in patients with axial spondyloarthritis (axSpA) who have been treated with the drug for a year and who have achieved sustained disease remission, regardless of subpopulation. However, complete treatment withdrawal is not recommended due to the high risk of flares [1,2]. Prof. Robert Landewé (University of Amsterdam, the Netherlands) presented the multicentre, 2-part, phase 3b C-OPTIMISE trial. Aim of the study was to determine the number of patients who remained free of disease flare after withdrawal or dose reduction of certolizumab pegol, by analysing whether responses to reduced maintenance dose were comparable in patients stratified by subpopulation, gender, and age. Eligible participants were patients with early axSpA, defi...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on